ERBB2 and neoplasm: Among those with invasive cancer, those who engaged in higher levels of PA were less likely to develop high-grade (moderate OR poorly vs. well differentiated (reference): 0.80 [0.65–0.97], p = 0.024) and HER2-positive (moderate OR HER2-negative vs. HER2-positive (reference): 1.18 [1.00–1.40], p = 0.048; vigorous OR HER2-negative vs. HER2-positive (reference): 1.33 [1.06–1.67], p = 0.015) tumour.